OBJECTIVE: To evaluate the prevalence of primary aldosteronism (PA) in newly diagnosed and untreated hypertensive patients in primary care using the aldosterone/renin ratio (ARR), and to assess clinical and biochemical characteristics in patients with high and normal ARR. DESIGN: Patient survey study. SETTING AND SUBJECTS: A total of 200 consecutive patients with newly diagnosed and untreated hypertension from six primary health care centres in Sweden were included. MAIN OUTCOME MEASURES: ARR was calculated from serum aldosterone and plasma renin concentrations. The cut-off level for ARR was 65. Patients with an increased ARR were considered for confirmatory testing with the fludrocortisone suppression test (FST), followed by adrenal computed tomographic radiology (CT) and adrenal venous sampling (AVS). RESULTS: Of 200 patients, 36 patients had an ARR > 65. Of these 36 patients, 11 patients had an incomplete aldosterone inhibition during FST. Three patients were diagnosed with an aldosterone producing adenoma (APA) and eight with bilateral adrenal hyperplasia (BHA). Except for moderately lower level of P-K in patients with an ARR > 65 and in patients with PA, there were no biochemical or clinical differences found among hypertensive patients with PA compared with patients without PA. CONCLUSION: Eleven of 200 evaluated patients (5.5%) were considered to have PA. The diagnosis of PA should therefore be considered in newly diagnosed hypertensive subjects and screening for the diagnosis is warranted.
OBJECTIVE: To evaluate the prevalence of primary aldosteronism (PA) in newly diagnosed and untreated hypertensivepatients in primary care using the aldosterone/renin ratio (ARR), and to assess clinical and biochemical characteristics in patients with high and normal ARR. DESIGN:Patient survey study. SETTING AND SUBJECTS: A total of 200 consecutive patients with newly diagnosed and untreated hypertension from six primary health care centres in Sweden were included. MAIN OUTCOME MEASURES: ARR was calculated from serum aldosterone and plasma renin concentrations. The cut-off level for ARR was 65. Patients with an increased ARR were considered for confirmatory testing with the fludrocortisone suppression test (FST), followed by adrenal computed tomographic radiology (CT) and adrenal venous sampling (AVS). RESULTS: Of 200 patients, 36 patients had an ARR > 65. Of these 36 patients, 11 patients had an incomplete aldosterone inhibition during FST. Three patients were diagnosed with an aldosterone producing adenoma (APA) and eight with bilateral adrenal hyperplasia (BHA). Except for moderately lower level of P-K in patients with an ARR > 65 and in patients with PA, there were no biochemical or clinical differences found among hypertensivepatients with PA compared with patients without PA. CONCLUSION: Eleven of 200 evaluated patients (5.5%) were considered to have PA. The diagnosis of PA should therefore be considered in newly diagnosed hypertensive subjects and screening for the diagnosis is warranted.
Authors: Paolo Mulatero; Robert G Dluhy; Gilberta Giacchetti; Marco Boscaro; Franco Veglio; Paul M Stewart Journal: Trends Endocrinol Metab Date: 2005-04 Impact factor: 12.015
Authors: G P Rossi; E Rossi; E Pavan; N Rosati; R Zecchel; A Semplicini; F Perazzoli; A C Pessina Journal: Clin Endocrinol (Oxf) Date: 1998-12 Impact factor: 3.478
Authors: Paolo Mulatero; Michael Stowasser; Keh-Chuan Loh; Carlos E Fardella; Richard D Gordon; Lorena Mosso; Celso E Gomez-Sanchez; Franco Veglio; William F Young Journal: J Clin Endocrinol Metab Date: 2004-03 Impact factor: 5.958
Authors: Lysann Seiler; Lars C Rump; Jürgen Schulte-Mönting; Marc Slawik; Katrin Borm; Hermann Pavenstädt; Felix Beuschlein; Martin Reincke Journal: Eur J Endocrinol Date: 2004-03 Impact factor: 6.664
Authors: K Nanba; M Tsuiki; K Nakao; A Nanba; T Usui; T Tagami; Y Hirokawa; H Okuno; T Suzuki; T Shimbo; A Shimatsu; M Naruse Journal: J Hum Hypertens Date: 2014-04-03 Impact factor: 3.012
Authors: Sabine C Käyser; Jaap Deinum; Wim Jc de Grauw; Bianca Wm Schalk; Hans Jhj Bor; Jacques Wm Lenders; Tjard R Schermer; Marion Cj Biermans Journal: Br J Gen Pract Date: 2018-01-15 Impact factor: 5.386